Advertisement

Ziconotide for Intrathecal Use

  • Corey W. HunterEmail author
  • Dipan Patel
Chapter

Abstract

Intrathecal drug delivery systems (IDDS) have been successfully utilized for both chronic, refractory cancer and non-cancer pain. Currently, only three pharmacologic agents are approved for intrathecal (IT) use by the Food and Drug Administration (FDA): morphine, baclofen, and ziconotide. Historically, morphine has been relied upon as a first-line agent for pain with (IT) therapy given its profound analgesic properties. However, even at the small doses typically used with IT therapy, morphine can lead to adverse events, complications with therapy, and even death. Baclofen is a power agent used for spasticity with no application in the treatment or management of chronic pain. Ziconotide is the only non-opioid analgesic agent currently available for IT use in the United States. Its pharmacologic effects are modulated via a selective block of presynaptic neuronal N-type calcium channels in the spinal cord. Given the unique mechanism of action of ziconotide, it holds significant advantages over IT opioids when implemented within IDDS. In this chapter, we will overview the current role of ziconotide for IT use in patients with refractory chronic pain.

Keywords

Neuromodulation Neuropathic pain Cancer pain Intrathecal drug delivery system Ziconotide Intrathecal pump Refractory chronic pain Nociceptive pain Intrathecal drug delivery system Chronic pain 

Recommended Readings

  1. 1.
    Ahmed S, Martin N, Chang Y. Patient selection and trial methods for Intraspinal drug delivery for chronic pain: a national survey. Neuromodulation. 2005;8(2):112–20.CrossRefGoogle Scholar
  2. 2.
    Bhatia G, Lau M, Gulur P. Intrathecal Drug Delivery (ITDD) systems for cancer pain. F1000Research, 2013.Google Scholar
  3. 3.
    Burton A, Rajagopal A, Shah H, Mendoza T, Cleeland C, Hassenbusch S, Arens J. Epidural and Intrathecal Analgesia is effective in treating refractory cancer pain. Pain Med. 2004;5(3):239–47.CrossRefGoogle Scholar
  4. 4.
    Burton AW, Deer TR, Wallace MS, Rauck RL, Grigsby E. Considerations and methodology for trialing ziconotide. Pain Physician. 2010;13:23–33.PubMedGoogle Scholar
  5. 5.
    Christo P, Bottros M. Current perspectives on intrathecal drug delivery. J Pain Res. 2014;7:615.CrossRefGoogle Scholar
  6. 6.
    Collins R, Lieberburg I, Ludington E, Howard R. Effectiveness of intrathecal ziconotide in multiple pain etiologies: a meta‐analysis of three controlled trials [abstract]. Pain Med. 2005;6:195.Google Scholar
  7. 7.
    Deer T, Caraway D, Wallace M. A definition of refractory pain to help determine suitability for device implantation. Neuromodulation. 2014;17(8):711–5.CrossRefGoogle Scholar
  8. 8.
    Deer TR, et al. The Polyanalgesic Consensus Conference (PACC): recommendations for trialing of Intrathecal drug delivery infusion therapy. Neuromodulation. 2017;20:133–54.  https://doi.org/10.1111/ner.12543.CrossRefPubMedGoogle Scholar
  9. 9.
    Deer TR, et al. The Polyanalgesic Consensus Conference (PACC): recommendations for Intrathecal drug delivery: guidance for improving safety and mitigating risks. Neuromodulation. 2017;20:155–76.  https://doi.org/10.1111/ner.12579.CrossRefGoogle Scholar
  10. 10.
    Deer TR, et al. The Polyanalgesic Consensus Conference (PACC): recommendations on Intrathecal drug infusion systems best practices and guidelines. Neuromodulation. 2017;20:96–132.  https://doi.org/10.1111/ner.12538.CrossRefGoogle Scholar
  11. 11.
    Deer T, et al. Effectiveness and safety of Intrathecal Ziconotide: Interim analysis of the patient registry of Intrathecal Ziconotide Management (PRIZM). Pain Pract. 2017;  https://doi.org/10.1111/papr.12599.CrossRefGoogle Scholar
  12. 12.
    Deer T, Rauck R, Kim P, Saulino M, Wallace M, Grigsby E, Huang I, Mori F, Vanhove G, McDowell G. Effectiveness and safety of Intrathecal Ziconotide: Interim analysis of the patient registry of Intrathecal Ziconotide Management (PRIZM). Pain Pract. 2017;18:230.CrossRefGoogle Scholar
  13. 13.
    Hayek S, Hanes M, Wang C, Veizi I. Ziconotide combination Intrathecal therapy for noncancer pain is limited secondary to delayed adverse effects: a case series with a 24-month follow-up. Neuromodulation. 2015;18(5):397–403.CrossRefGoogle Scholar
  14. 14.
    Hunter C, Diwan S, Deer T. Neuroaugmentation by stimulation vs. Intrathecal drug delivery. In: Intrathecal pump delivery for pain and spasticity, vol. 2. Philadelphia: Elsevier; 2012.Google Scholar
  15. 15.
    Maeyaert J, Buchser E, Van Buyten J, Rainov N, Becker R. Patient-controlled Analgesia in Intrathecal therapy for chronic pain: safety and effective operation of the Model 8831 personal therapy manager with a pre-implanted synchromed infusion system. Neuromodulation. 2003;6(3):133–41.CrossRefGoogle Scholar
  16. 16.
    McDowell GC. Use of the personal therapy manager with Prialt® (ziconotide) for patient‐controlled analgesia: a case series highlighting techniques and outcomes. Las Vegas. Presented at the 14th Annual Meeting of the North American Neuromodulation Society, December 2–5, 2010. http://www.slideserve.com/uri/use-of-the-personal-therapy-manager-with-prialt-ziconotide-intrathecal-infusion-for-patient-controlled-analgesia-case. Accessed 28 Aug 2017.
  17. 17.
    McDowell GC, Pope JE. Intrathecal Ziconotide: dosing and administration strategies in patients with refractory chronic pain. Neuromodulation. 2016;19(5):522–32.  https://doi.org/10.1111/ner.12392.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    McGivern J. Ziconotide: a review of its pharmacology and use in the treatment of pain. Neuropsychiatr Dis Treat. 2007;3(1):69–85.CrossRefGoogle Scholar
  19. 19.
    Patel D, Dang S, Weber G. Neuromodulation of cancer pain. Top Pain Manag. 2016;31(12):1–10.CrossRefGoogle Scholar
  20. 20.
    Pope JE, Deer TR. Intrathecal ziconotide in the treatment of failed back surgery syndrome. Pain Med News Spec Ed. 2014:79–80.Google Scholar
  21. 21.
    Pope JE, Deer TR. Intrathecal pharmacology update: novel dosing strategy for intrathecal monotherapy ziconotide on efficacy and sustainability. Neuromodulation. 2015;18:414–20.CrossRefGoogle Scholar
  22. 22.
    PRIALT [package insert] Jazz Pharmaceuticals: Palo Alto; 2013.Google Scholar
  23. 23.
    Rauck R, Wallace M, Leong M, Minehart M, Webster L, Charapata S, Abraham J, Buffington D, Ellis D, Kartzinel R. A randomized, double-blind, placebo-controlled study of Intrathecal Ziconotide in adults with severe chronic pain. J Pain Symptom Manag. 2006;31(5):393–406.CrossRefGoogle Scholar
  24. 24.
    Rauck R, Wallace M, Burton A, Kapural L, North J. Intrathecal Ziconotide for neuropathic pain: a review. Pain Pract. 2009;9(5):327–37.CrossRefGoogle Scholar
  25. 25.
    Sanford M. Intrathecal Ziconotide: a review of its use in patients with chronic pain refractory to other systemic or Intrathecal Analgesics. CNS Drugs. 2013;27(11):989–1002.CrossRefGoogle Scholar
  26. 26.
    Saulino M, Kim P, Shaw E. Practical considerations and patient selection for intrathecal drug delivery in the management of chronic pain. J Pain Res. 2014:627.Google Scholar
  27. 27.
    Smith T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002;20(19):4040–9.CrossRefGoogle Scholar
  28. 28.
    Staats P, Yearwood T, Charapata S, Presley R, Wallace M, Byas-Smith M, Fisher R, Bryce D, Mangieri E, Luther R, Mayo M, McGuire D, Ellis D. Intrathecal Ziconotide in the treatment of refractory pain in patients with cancer or AIDS. JAMA. 2004;291(1):63.CrossRefGoogle Scholar
  29. 29.
    Stearns L, Boortz‐Marx R, Du PS, et al. Intrathecal drug delivery for the management of cancer pain: a multidisciplinary consensus of best clinical practices. J Support Oncol. 2005;3:399–408.Google Scholar
  30. 30.
    Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990‐2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163–96.CrossRefGoogle Scholar
  31. 31.
    Wallace M, Charapata S, Fisher R, Byas-Smith M, Staats P, Mayo M, McGuire D, Ellis D. Intrathecal Ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, Placebo-controlled clinical trial. Neuromodulation. 2006;9(2):75–86.CrossRefGoogle Scholar
  32. 32.
    Webster L. The relationship between the mechanisms of action and safety profiles of Intrathecal Morphine and Ziconotide: a review of the literature. Pain Med. 2015;16(7):1265–77.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Rehabilitation MedicineIcahn School of Medicine at Mount SinaiNew YorkUSA
  2. 2.Ainsworth Institute of Pain ManagementNew YorkUSA
  3. 3.Garden State Pain Control CenterCliftonUSA
  4. 4.Residents & Fellows SocietyNorth American Neuromodulation Society (NANS)Jersey CityUSA

Personalised recommendations